New cancer drug trial pulled before it even started
NCT ID NCT07570966
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ERW316 (oral drug)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced breast cancer and other solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data is available. It is very early-stage research, and the drug may not prove safe or effective in humans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CCNE1-AMPLIFIED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Blood test could tell doctors when to stop prostate cancer treatment early
- New pill targets cancer growth at the genetic level
- Blood test timing could unlock secrets of advanced breast cancer
- Real-World study eyes drug combo for tough prostate cancer
- New radioactive therapy targets Hard-to-Treat prostate cancer